Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)

Inclusion Criteria: * Male or female participants ≥18 and ≤90 years of age. * Onset of symptoms ≥48 hours after admission or \<7 days after discharge from an inpatient acute or chronic care facility. * New or worsening infiltrate on chest X-ray obtained within 48 hours prior to screening. * Participants have systemic signs and respiratory signs or symptoms of HAP/VAP Exclusion Criteria: * Other medical or psychiatric condition may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * Participant is expected to require a treatment course for HAP longer than 14 days. * The total duration of antibiotic exposure for antibiotics whose administration begins in the 48 hours is longer than 24 hours. * Previous administration with an investigational drug within 30 days or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer). * Acute Physiology and Chronic Health Evaluation (APACHE) II score \>30 or \<10 using the most recent available data.